Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2025)

Arcus Biosciences has reported Current Deferred Revenue over the past 9 years, most recently at $78.0 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $78.0 million for Q4 2025, down 75.55% from a year ago — trailing twelve months through Dec 2025 was $78.0 million (down 75.55% YoY), and the annual figure for FY2025 was $78.0 million, down 75.55%.
  • Current Deferred Revenue for Q4 2025 was $78.0 million at Arcus Biosciences, down from $105.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RCUS hit a ceiling of $366.0 million in Q1 2024 and a floor of $35.0 million in Q2 2023.
  • Median Current Deferred Revenue over the past 5 years was $97.0 million (2022), compared with a mean of $122.6 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 965.3% in 2021 and later crashed 80.33% in 2025.
  • Arcus Biosciences' Current Deferred Revenue stood at $102.0 million in 2021, then decreased by 4.9% to $97.0 million in 2022, then crashed by 63.92% to $35.0 million in 2023, then surged by 811.43% to $319.0 million in 2024, then tumbled by 75.55% to $78.0 million in 2025.
  • The last three reported values for Current Deferred Revenue were $78.0 million (Q4 2025), $105.0 million (Q3 2025), and $71.0 million (Q2 2025) per Business Quant data.